Saba Capital Reaches Agreements with Two BlackRock Closed-End Funds
MWN-AI** Summary
Saba Capital Management, L.P. has announced agreements with BlackRock Advisors, LLC to initiate cash tender offers for two BlackRock closed-end funds: the BlackRock Innovation and Growth Term Trust (BIGZ) and the BlackRock Health Sciences Term Trust (BMEZ). The agreements stem from constructive negotiations and involve purchasing 50% of the outstanding shares for BIGZ and 40% for BMEZ at a price equivalent to 99.5% of the funds' net asset value (NAV). The tender offers are set to begin on March 21, 2025, for BMEZ and June 9, 2025, for BIGZ, with a closing period extending to the 20th business day after their commencement.
Notably, this opportunity allows shareholders to tender either some or all of their shares at a competitive price based on the NAV, providing liquidity in the marketplace. The funds are obligated to pay for any common shares tendered within seven business days following the expiration of these offers. Saba Capital, in addition to participating in the tender offers, has agreed to withdraw previously submitted shareholder proposals and will comply with certain standstill covenants for three years, extending through the 2027 proxy season.
Founded in 2009 by Boaz Weinstein, Saba Capital is recognized for its innovative approach to credit strategies and capital structure arbitrage. The firm is headquartered in New York City and London, aiming to generate superior risk-adjusted returns for a diverse clientele. The full details of these agreements will be filed with the Securities and Exchange Commission, further ensuring transparency and regulatory compliance in this strategic move.
MWN-AI** Analysis
Saba Capital Management's recent agreements with BlackRock Advisors concerning the BlackRock Innovation and Growth Term Trust (BIGZ) and the BlackRock Health Sciences Term Trust (BMEZ) present an intriguing investment opportunity for market participants. Given that both funds will be conducting cash tender offers at an attractive 99.5% of their net asset value (NAV), investors should closely examine these developments.
The tender offers, which aim to repurchase 50% of BIGZ’s shares and 40% of BMEZ’s, signal a proactive approach by Saba to enhance shareholder value amid potential undervaluation. This situation is noteworthy as it offers existing shareholders an opportunity to realize their investment at a premium to the current trading prices, thereby incentivizing participation in the offers. Investors considering tendering their shares should weigh the benefits of immediate liquidity against the long-term growth potential of remaining invested in funds managed by a robust investment advisor like BlackRock.
Moreover, Saba’s strategic decision to withdraw its shareholder proposals in exchange for these agreements underscores a commitment to collaborating with fund management, potentially leading to more favorable outcomes for shareholders in the future. This standstill arrangement also indicates a level of confidence from Saba in the management's capacity to enhance fund performance over the next three years.
Investors should monitor the execution of these tender offers closely. The upcoming commencement dates, March 21, 2025, for BMEZ and June 9, 2025, for BIGZ, provide a clear timeline for strategic planning. Additionally, assessing the unique investment focuses of BIGZ and BMEZ—technology-driven innovation and healthcare sciences—will be crucial as market demands evolve post-offer period. Overall, this development highlights a dynamic market where strategic negotiations and shareholder actions can significantly impact investment outcomes.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BlackRock Innovation and Growth Term Trust and BlackRock Health Sciences Term Trust Will Conduct Cash Tender Offers for 50% of Shares and 40% of Shares, Respectively, at 99.5% of NAV
Saba Capital Management, L.P. (together with certain of its affiliates, “Saba”) today announced that it has entered into standstill agreements (the “Agreements”) with BlackRock Advisors, LLC, which is the investment advisor of the BlackRock Innovation and Growth Term Trust (NYSE: BIGZ) and the BlackRock Health Sciences Term Trust (NYSE: BMEZ) (the “Funds”), following constructive negotiations. Under the terms of the Agreements, BIGZ will conduct a tender offer to purchase for cash 50% of its outstanding common shares and BMEZ will conduct a tender offer to purchase for cash 40% of its outstanding common shares (the “Tender Offers”). The Tender Offers will provide all shareholders the opportunity to tender some or all of their common shares at a price equal to 99.5% of the Funds’ net asset value per share (“NAV”) as determined as of the close of the regular trading session of the New York Stock Exchange (the “NYSE”) on the trading day after the expiration or closing date of the Tender Offers.
The Tender Offers are expected to commence on March 21, 2025, in the case of BMEZ, and on June 9, 2025, in the case of BIGZ, and will expire or close on the 20 th business day after their commencement and the Funds will pay for any Common Shares tendered no later than the seventh business day after the expiration or closing of the Tender Offers.
The terms of the Agreements also provide for Saba to tender all of its Common Shares of the Funds and withdraw the shareholder proposals it submitted to the Funds, in addition to complying with certain standstill covenants for a period of three years, encompassing the 2027 proxy season.
The full Agreements will be filed with the Securities and Exchange Commission.
About Saba Capital
Saba Capital Management, L.P. is a global alternative asset management firm that seeks to deliver superior risk-adjusted returns for a diverse group of clients. Founded in 2009 by Boaz Weinstein, Saba is a pioneer of credit relative value strategies and capital structure arbitrage. Saba has offices in New York City and London. Learn more at www.sabacapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121439547/en/
Longacre Square Partners
Charlotte Kiaie / Kate Sylvester, 646-386-0091
ckiaie@longacresquare.com / ksylvester@longacresquare.com
FAQ**
How will the cash tender offers for 50% of the shares of BlackRock Innovation and Growth Trust of Beneficial Interest BIGZ impact existing shareholders' value and liquidity in the trust?
What are the strategic implications for Saba Capital Management in entering into the standstill agreements regarding BlackRock Innovation and Growth Trust of Beneficial Interest BIGZ?
How does the execution of tender offers at 99.5% of NAV for BlackRock Innovation and Growth Trust of Beneficial Interest BIGZ compare to past tender offers in the market?
What potential risks should investors consider regarding the timing and effects of the tender offers for BlackRock Innovation and Growth Trust of Beneficial Interest BIGZ and BlackRock Health Sciences Term Trust?
**MWN-AI FAQ is based on asking OpenAI questions about BlackRock Health Sciences Term Trust of Beneficial Interest (NYSE: BMEZ).
NASDAQ: BMEZ
BMEZ Trading
1.74% G/L:
$14.64 Last:
219,134 Volume:
$14.58 Open:
